ALDX (Aldeyra Therapeutics Inc.) stock: $0.63, $38.2M market cap, $41.0M cash, -$2.8M EV, $46.5M fully diluted market cap. Next expected readout: Dec-26. Lead program: ICM ADX-2191 injection (Primary Vitreoretinal Lymphoma), Phase 3. Data from Fully Diluted's biotech stocks database.
What they do
Aldeyra Therapeutics is a biotechnology company devoted to discovering innovative therapies designed to treat immune-mediated diseases. Our approach is to develop pharmaceuticals that modulate protein systems, instead of directly inhibiting or activating single protein targets, with the goal of optimizing multiple pathways at once while minimizing toxicity.
Estimated readout windows: registry primary-completion date + 6-12 weeks. Windows already open are shown from "Now". Drug names link to ClinicalTrials.gov.
Partnerships AbbVie Inc: exclusive option agreement to enter a collaboration to develop/manufacture/commercialize reproxalap in the U.S. ($100M upfront on collaboration entry); option exercise period extended via $5M non-refundable fee; option tied to the FDA decision on the reproxalap NDA
Indications
Dry eye disease(Stage not disclosed)
Status note RASP modulator; NDA resubmission for dry eye disease pending FDA decision (the Reproxalap NDA). Filing states no clinical stage and no dated catalyst.
ADX-2191
Stage not disclosed · Active
Target Dihydrofolate reductase (DHFR)
Partnerships Licensed from MEEI (MEEI Patent Rights); proliferative-vitretinopathy rights obtained via Helio merger agreement
Indications
Primary vitreoretinal lymphoma(Stage not disclosed)
Retinitis pigmentosa(Stage not disclosed)
Proliferative vitreoretinopathy(Stage not disclosed)
Status note Novel formulation of intravitreal methotrexate per filing. Filing states no clinical stage and no dated catalyst.
ADX-248
Stage not disclosed · Active
Target reactive aldehyde species (RASP)
Indications
Systemic immune-mediated diseases(Stage not disclosed)
Retinal immune-mediated diseases(Stage not disclosed)
Status note RASP modulator portfolio asset. Filing lists it among compounds to advance through preclinical and clinical development but states no per-asset clinical stage.
ADX-246
Stage not disclosed · Active
Target reactive aldehyde species (RASP)
Indications
Systemic immune-mediated diseases(Stage not disclosed)
Retinal immune-mediated diseases(Stage not disclosed)
Status note RASP modulator portfolio asset. Filing lists it among compounds to advance through preclinical and clinical development but states no per-asset clinical stage.
ADX-629
Stage not disclosed · Terminated
Target reactive aldehyde species (RASP)
Status note Described in the filing as a signal-finding molecule no longer under development.
Per-asset detail extracted from the 10-Q filed 2026-08-06. Fields the filing does not state are marked "not disclosed" rather than filled from other sources.
Sponsor-matched active trials from ClinicalTrials.gov (1 as sponsor, 0 as collaborator); "Sponsor" = company is the lead sponsor, "Collaborator" = company is a collaborator. The BP column flags big-pharma involvement as lead sponsor or collaborator (excluding the company itself). The Mgmt guide column shows what management guided for readout timing when a guided program matches the trial (hover for the quote, click for the source). Trial listings are not a company pipeline slide.